Navigation Links
US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications

Patent Protection extends at least to 2025

Hamilton, NJ (PRWEB) June 4, 2010 -- Chrono Therapeutics Inc. (Chrono), a privately held company that pioneers chrono therapeutic health care products, announced today that it has been awarded another United States patent to protect its chrono-pharmacological systems and applications.

Guy DiPierro, CEO of Chrono, noted that this new patent grant enhances Chrono’s exclusivity for what is believed to be the next revolutionary change in therapeutics-namely tailored chrono-pharmacological therapies. Mr DiPierro noted that this new patent grant also affirms the novelty of Chrono’s technology and believes it will considerably reduce any potential risk to the Chrono group.

About Chrono Therapeutics Inc. Intellectual Property (IP)

Chrono Therapeutics’ IP estate includes issued, allowed, and granted fundamental patents in several of the world’s major pharmaceutical markets. This IP protects Chrono’s chrono-pharmacological applications and non-invasive drug delivery systems. Additional patents are and will soon be pending worldwide.

About Chrono Therapeutics Inc.

Chrono Therapeutics Inc. is specialty pharmaceutical company developing novel therapeutic systems and methods to become the global leader in Chrono Therapeutic based drug products. The significant advantages of chrono therapeutic based therapies have now become widely recognized and are quickly coming to the forefront as the next major advance in treating indications. The company is applying its therapeutic expertise to develop these chrono therapeutic and tailored applications that seek to dramatically increase efficacy over traditional non-tailored applications while decreasing adverse side effects and accumulated tolerance. The company’s leadership with chrono therapeutic optimized application and methodologies and fundamental patents, technology, and know-how has proven key in forming major alliances with leading companies worldwide.

Chrono Therapeutics Inc.
Guy DiPierro, Chief Executive Officer
Email: Info(at)ChronoDose(dot)com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
2. Haemonetics Files a New Legal Action to Stop Fenwal Inc.s Continued Patent Infringement
3. United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software
4. OmniActive and Kemin Reach Amicable Settlement in Patent Dispute
5. Patent Granted on GenerOs EX, A Medical Device That Helps Bones Grow
6. American Diversified Holdings Corporation Announces Stem Cell Patent Acquisition Program
7. MindUp (HIRU) Patents in the World Patent Database
8. GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases
9. Verdan Receives Patent on Crystal Deodorant Spray
10. Expands Into Medical Wristbands Market with Patented LaserBand Printable Wristbands
11. Sandata Technologies and Infocrossing Settle Patent Infringement Suit
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: